Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD465 in Adults With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of ADHD using DSM-IV-TR criteria (at least 6 of the 9 subtype criteria met)~* Baseline ADHD-RS-IV score =\>24~* IQ score of =\> 80 (using Kaufman Brief Intelligence Test)~Exclusion Criteria:~* BMI \< 18.5 or \> 30 kg/m2~* Diagnosis of Post Traumatic Stress Disorder, psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder~* History of seizure disorder or a lifetime history of any seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder~* History of uncontrolled hypertension or currently hypertensive~* Subjects who have taken atomoxetine (STRATTERA) within 30 days prior to screening~* Current (or history within the last 12 months) of drug dependence or substance abuse disorder according to DSM-IV-TR criteria (excluding nicotine)~* Female subject is pregnant or lactating, less than 3 months post partum

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).